When neither an HLA-matched family member or a suitable matched-unrelated donor is available for a patient in need of a hematopoietic cell transplant, the question of cord blood transplantation arises. Recent advances in the field make this option increasingly attractive; among the alternative options is to not do a transplant even for patients with bona fide indications. (One must also keep in mind that for some patients, particularly in the pediatric age group, many transplant physicians consider cord bloods to be the hematopoietic stem cell source of choice.)

There are a number of issues regarding the selection of the optimal unit for transplantation that are different for cord blood units vs. PBSC or BMT units, including HLA-matching and prioritization of HLA-match vs. cell dose. Recent data regarding these and other points are categorized into the following topics for ease of review. Click on any of the following topics, including any of the recent and authoritative reviews to evaluate current data. You may also search for any topic and/or author by clicking on the SEARCH link in the navigation menu to access our comprehensive site search feature.

Please note that a link to an online abstract or full text version of each article is provided, if publicly available. Individuals with subscriptions to the journal may have online access to full text articles with a member sign-in on the journal's website. ASH members have online access to all full text articles published in Blood (initial sign-in required).

CordBloodForum.org would appreciate comments and questions.

0.	THE TOP TEN
I.	RECENT REVIEWS
II.	TRANSPLANTATION OF ADULTS
III.	MULTI-CORD TRANSPLANTS
IV.	REDUCED INTENSITY AND NON-MYELOABLATIVE TRANSPLANTS
	i.	CORD BLOOD TRANSPLANTS
	ii.	MARROW AND PBSC TRANSPLANTS
V.	DONOR SELECTION FOR UNRELATED CORD BLOOD TRANSPLANTATION
VI.	AVAILABILITY AND TIME REQUIRED TO OBTAIN CORD BLOOD VERSUS BONE MARROW
VII.	CORD BLOOD TRANSPLANTATION IN CHILDREN
	i.	MALIGNANT DISORDERS
	ii.	CONGENITAL DISORDERS
	iii.	ACQUIRED NON-MALIGNANT DISORDERS
VIII.	GRAFT-VERSUS HOST DISEASE (GVHD)
	i.	GVHD IN BMT AND PBSC HEMATOPOIETIC CELL TRANSPLANTS
IX.	HLA MATCHING
X.	GRAFT-VERSUS-LEUKEMIA (GVL) ACTIVITY
XI.	RECENT CORD BLOOD TRANSPLANTATION CONFERENCES
XII.	SICKLE CELL DISEASE AND THALASSEMIA
	i.	SICKLE CELL DISEASE
		A. CLINICAL ASPECTS
		B. NEUROLOGIC COMPLICATIONS
		C. BONE MARROW AND PBSC TRANSPLANTATION
		D. UMBILICAL CORD BLOOD TRANSPLANTATION
	ii.	THALASSEMIA
		A. CLINICAL ASPECTS
		B. BONE MARROW AND PBSC TRANSPLANTATION
		C. UMBILICAL CORD BLOOD TRANSPLANTATION
		D. IRON OVERLOAD AND CHELATION
XIII.	IMMUNE RECONSTITUTION
XIV.	ADVERSE EVENTS IN CORD BLOOD TRANSPLANTATION
	i.	INFECTIONS (OTHER THAN EBV)
	ii.	EBV INFECTIONS / POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD)
	iii.	IMMUNE CYTOPENIA
	iv.	DONOR-DERIVED LEUKEMIA
	v.	MISCELLANEOUS
XV.	NEW CONCEPTS IN CORD BLOOD TRANSPLANTATION
	i.	ADOPTIVE IMMUNOTHERAPY AFTER CBT
	ii.	CO-TRANSPLANTATION OF CORD BLOOD UNITS AND MOBILIZED STEM CELLS FROM A THIRD PARTY DONOR
	iii.	PREIMPLANTATION GENETIC DIAGNOSIS
	iv.	IN-VIVO EXPANSION OF CORD BLOOD STEM CELLS
	v.	SERIAL TRANSPLANTATION RESULTING IN TOLERANCE
XVI.	STEM CELL PLASTICITY AND REGENERATIVE MEDICINE
XVII.	RELATED CORD BLOOD TRANSPLANTATION
XVIII.	EX-VIVO EXPANSION OF HEMATOPOIETIC PROGENITOR CELLS
XIX.	MISCELLANEOUS TOPICS
	i.	MESENCHYMAL STEM CELLS
	ii.	GRANULOCYTE TRANSFUSION
	iii.	REGULATORY ISSUES
	iv.	AUTOIMMUNE DISEASES
	v.	HIV POSITIVE PATIENTS
	vi.	ACUTE RADIATION INJURY
	vii.	OTHER ITEMS
XX.	ARTICLES REGARDING BMT AND/OR PBSC WITH RELEVANCE TO CORD BLOOD TRANSPLANTATION
XXI.	CORD BLOOD BANKING
	i.	OVERVIEW
	ii.	INFORMED CONSENT
	iii.	STRATEGIES FOR CORD BLOOD COLLECTION
	iv.	PROCESSING, CYROPRESERVATION AND INFUSION
	v.	QUALITY ISSUES
XXII.	BOOKS
XXIII.	AMERICAN SOCIETY OF HEMATOLOGY (ASH) ABSTRACTS 2007

Back to Top